Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 7/20 | 0.49 |
| ▸ | JAK1 | P23458 | 6/20 | 0.49 |
| ▸ | JAK2 | O60674 | 5/20 | 0.49 |
| ▸ | EGFR | P00533 | 5/20 | 0.48 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.48 |
| ▸ | MAP2K7 | O14733 | 3/20 | 0.48 |
| ▸ | TYK2 | P29597 | 1/20 | 0.48 |
| ▸ | MET | P08581 | 2/20 | 0.48 |
| ▸ | BTK | Q06187 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL690656 | 0.90 | MET (0.51) | JAK3JAK1JAK2EGFRERBB2 | |
| SCHEMBL18001184 | 0.73 | EGFR (0.59) | JAK3JAK1JAK2EGFRTYK2 | |
| SCHEMBL10127822 | 0.72 | CTSC (0.69) | JAK3JAK1JAK2EGFRMAP2K7 | |
| SCHEMBL16146028 | 0.72 | MAP2K7 (0.49) | JAK3JAK1JAK2EGFRERBB2 | |
| SCHEMBL2315212 | 0.71 | EGFR (0.42) | EGFRERBB2MAP2K7METBTK | |
| SCHEMBL693272 | 0.70 | MAP2K7 (0.50) | JAK3JAK1JAK2EGFRERBB2 | |
| SCHEMBL16665293 | 0.70 | MAPK10 (0.52) | EGFRERBB2MAP2K7BTK | |
| SCHEMBL12262617 | 0.70 | PIK3CA (0.51) | EGFRMAP2K7MET | |
| SCHEMBL12262594 | 0.70 | MAP2K7 (0.49) | JAK3JAK1JAK2EGFRERBB2 | |
| SCHEMBL30823222 | 0.70 | BTK (0.42) | JAK3JAK1JAK2EGFRTYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160279127-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. | 2016-09-29 | — | — | US | disclosed |
| US-20160279127-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. | 2016-09-29 | — | — | US | disclosed |
| US-20160279127-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. | 2016-09-29 | — | — | US | disclosed |
| US-9296704-B2 | Substituted pyrimidines as protein kinase inhibitors | CELGENE AVILOMICS RESEARCH, INC. (US) | 2016-03-29 | — | — | US | disclosed |
| US-9296704-B2 | Substituted pyrimidines as protein kinase inhibitors | CELGENE AVILOMICS RESEARCH, INC. (US) | 2016-03-29 | — | — | US | disclosed |
| US-9296704-B2 | Substituted pyrimidines as protein kinase inhibitors | CELGENE AVILOMICS RESEARCH, INC. (US) | 2016-03-29 | — | — | US | disclosed |
| US-20140303165-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. | 2014-10-09 | — | — | US | disclosed |
| US-20140303165-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. | 2014-10-09 | — | — | US | disclosed |
| US-20140303165-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. | 2014-10-09 | — | — | US | disclosed |
| US-8748606-B2 | 4,6-diaminopyrimidines useful as kinase inhibitors | CELGENE AVILOMICS RESEARCH, INC. (US) | 2014-06-10 | — | — | US | disclosed |
| US-20110224432-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2011-09-15 | — | — | US | disclosed |
| US-20110224432-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2011-09-15 | — | — | US | disclosed |
| US-7989465-B2 | 4,6-disubstituted pyrimidines useful as kinase inhibitors | AVILA THERAPEUTICS, INC. (US) | 2011-08-02 | — | — | US | disclosed |
| US-7989465-B2 | 4,6-disubstituted pyrimidines useful as kinase inhibitors | AVILA THERAPEUTICS, INC. (US) | 2011-08-02 | — | — | US | disclosed |
| US-7989465-B2 | 4,6-disubstituted pyrimidines useful as kinase inhibitors | AVILA THERAPEUTICS, INC. (US) | 2011-08-02 | — | — | US | disclosed |
| WO-2010123870-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2010-10-28 | — | — | WO | disclosed |
| WO-2010123870-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2010-10-28 | — | — | WO | disclosed |
| US-20100016296-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2010-01-21 | — | — | US | disclosed |
| US-20100016296-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2010-01-21 | — | — | US | disclosed |
| US-20100016296-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2010-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160279127-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | JAK3 439/4885JAK1 2115/4885JAK2 258/4885 |
| US-20100016296-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | JAK3 439/4885JAK1 2115/4885JAK2 258/4885 |
| US-20110224432-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | JAK3 439/4885JAK1 2115/4885JAK2 258/4885 |
| US-20140303165-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | JAK3 439/4885JAK1 2115/4885JAK2 258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.